2104 related articles for article (PubMed ID: 28724768)
1. Synthetic Toll-Like Receptor 4 (TLR4) and TLR7 Ligands Work Additively via MyD88 To Induce Protective Antiviral Immunity in Mice.
Goff PH; Hayashi T; He W; Yao S; Cottam HB; Tan GS; Crain B; Krammer F; Messer K; Pu M; Carson DA; Palese P; Corr M
J Virol; 2017 Oct; 91(19):. PubMed ID: 28724768
[TBL] [Abstract][Full Text] [Related]
2. Synthetic Toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responses.
Goff PH; Hayashi T; Martínez-Gil L; Corr M; Crain B; Yao S; Cottam HB; Chan M; Ramos I; Eggink D; Heshmati M; Krammer F; Messer K; Pu M; Fernandez-Sesma A; Palese P; Carson DA
J Virol; 2015 Mar; 89(6):3221-35. PubMed ID: 25568203
[TBL] [Abstract][Full Text] [Related]
3. A Novel Synthetic Dual Agonistic Liposomal TLR4/7 Adjuvant Promotes Broad Immune Responses in an Influenza Vaccine With Minimal Reactogenicity.
Sato-Kaneko F; Yao S; Lao FS; Shpigelman J; Messer K; Pu M; Shukla NM; Cottam HB; Chan M; Chu PJ; Burkhart D; Schoener R; Matsutani T; Carson DA; Corr M; Hayashi T
Front Immunol; 2020; 11():1207. PubMed ID: 32636840
[TBL] [Abstract][Full Text] [Related]
4. TLR7 recognition is dispensable for influenza virus A infection but important for the induction of hemagglutinin-specific antibodies in response to the 2009 pandemic split vaccine in mice.
Jeisy-Scott V; Kim JH; Davis WG; Cao W; Katz JM; Sambhara S
J Virol; 2012 Oct; 86(20):10988-98. PubMed ID: 22837197
[TBL] [Abstract][Full Text] [Related]
5. Novel Lipidated Imidazoquinoline TLR7/8 Adjuvants Elicit Influenza-Specific Th1 Immune Responses and Protect Against Heterologous H3N2 Influenza Challenge in Mice.
Miller SM; Cybulski V; Whitacre M; Bess LS; Livesay MT; Walsh L; Burkhart D; Bazin HG; Evans JT
Front Immunol; 2020; 11():406. PubMed ID: 32210973
[TBL] [Abstract][Full Text] [Related]
6. Adjuvanting a Simian Immunodeficiency Virus Vaccine with Toll-Like Receptor Ligands Encapsulated in Nanoparticles Induces Persistent Antibody Responses and Enhanced Protection in TRIM5α Restrictive Macaques.
Kasturi SP; Kozlowski PA; Nakaya HI; Burger MC; Russo P; Pham M; Kovalenkov Y; Silveira ELV; Havenar-Daughton C; Burton SL; Kilgore KM; Johnson MJ; Nabi R; Legere T; Sher ZJ; Chen X; Amara RR; Hunter E; Bosinger SE; Spearman P; Crotty S; Villinger F; Derdeyn CA; Wrammert J; Pulendran B
J Virol; 2017 Feb; 91(4):. PubMed ID: 27928002
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant use of the NKT cell agonist alpha-galactosylceramide leads to enhancement of M2-based DNA vaccine immunogenicity and protective immunity against influenza A virus.
Fotouhi F; Shaffifar M; Farahmand B; Shirian S; Saeidi M; Tabarraei A; Gorji A; Ghaemi A
Arch Virol; 2017 May; 162(5):1251-1260. PubMed ID: 28120096
[TBL] [Abstract][Full Text] [Related]
8. Broadly Protective CD8
Zhang H; Zheng H; Guo P; Hu L; Wang Z; Wang J; Ju Y; Meng S
J Virol; 2021 May; 95(12):. PubMed ID: 33827939
[TBL] [Abstract][Full Text] [Related]
9. Enhanced Influenza Virus-Like Particle Vaccination with a Structurally Optimized RIG-I Agonist as Adjuvant.
Beljanski V; Chiang C; Kirchenbaum GA; Olagnier D; Bloom CE; Wong T; Haddad EK; Trautmann L; Ross TM; Hiscott J
J Virol; 2015 Oct; 89(20):10612-24. PubMed ID: 26269188
[TBL] [Abstract][Full Text] [Related]
10. MyD88 signaling is indispensable for primary influenza A virus infection but dispensable for secondary infection.
Seo SU; Kwon HJ; Song JH; Byun YH; Seong BL; Kawai T; Akira S; Kweon MN
J Virol; 2010 Dec; 84(24):12713-22. PubMed ID: 20943980
[TBL] [Abstract][Full Text] [Related]
11. The optimized fusion protein HA1-2-FliCΔD2D3 promotes mixed Th1/Th2 immune responses to influenza H7N9 with low induction of systemic proinflammatory cytokines in mice.
Song L; Xiong D; Kang X; Jiao Y; Zhou X; Wu K; Zhou Y; Jiao X; Pan Z
Antiviral Res; 2019 Jan; 161():10-19. PubMed ID: 30389471
[TBL] [Abstract][Full Text] [Related]
12. Vaccination with Vesicular Stomatitis Virus-Vectored Chimeric Hemagglutinins Protects Mice against Divergent Influenza Virus Challenge Strains.
Ryder AB; Nachbagauer R; Buonocore L; Palese P; Krammer F; Rose JK
J Virol; 2015 Dec; 90(5):2544-50. PubMed ID: 26676789
[TBL] [Abstract][Full Text] [Related]
13. DAMP-Inducing Adjuvant and PAMP Adjuvants Parallelly Enhance Protective Type-2 and Type-1 Immune Responses to Influenza Split Vaccination.
Hayashi T; Momota M; Kuroda E; Kusakabe T; Kobari S; Makisaka K; Ohno Y; Suzuki Y; Nakagawa F; Lee MSJ; Coban C; Onodera R; Higashi T; Motoyama K; Ishii KJ; Arima H
Front Immunol; 2018; 9():2619. PubMed ID: 30515151
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-1 family cytokines as mucosal vaccine adjuvants for induction of protective immunity against influenza virus.
Kayamuro H; Yoshioka Y; Abe Y; Arita S; Katayama K; Nomura T; Yoshikawa T; Kubota-Koketsu R; Ikuta K; Okamoto S; Mori Y; Kunisawa J; Kiyono H; Itoh N; Nagano K; Kamada H; Tsutsumi Y; Tsunoda S
J Virol; 2010 Dec; 84(24):12703-12. PubMed ID: 20881038
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity of modified vaccinia virus Ankara expressing the hemagglutinin stalk domain of pandemic (H1N1) 2009 influenza virus.
Di Mario G; Soprana E; Gubinelli F; Panigada M; Facchini M; Fabiani C; Garulli B; Basileo M; Cassone A; Siccardi A; Donatelli I; Castrucci MR
Pathog Glob Health; 2017 Mar; 111(2):69-75. PubMed ID: 28081672
[TBL] [Abstract][Full Text] [Related]
16. The virus-induced signaling adaptor molecule enhances DNA-raised immune protection against H5N1 influenza virus infection in mice.
Luo M; Qu X; Pan R; Zhu D; Zhang Y; Wu J; Pan Z
Vaccine; 2011 Mar; 29(14):2561-7. PubMed ID: 21303708
[TBL] [Abstract][Full Text] [Related]
17. Inactivated H7 Influenza Virus Vaccines Protect Mice despite Inducing Only Low Levels of Neutralizing Antibodies.
Kamal RP; Blanchfield K; Belser JA; Music N; Tzeng WP; Holiday C; Burroughs A; Sun X; Maines TR; Levine MZ; York IA
J Virol; 2017 Oct; 91(20):. PubMed ID: 28768855
[TBL] [Abstract][Full Text] [Related]
18. Modified vaccinia virus Ankara encoding influenza virus hemagglutinin induces heterosubtypic immunity in macaques.
Florek KR; Weinfurter JT; Jegaskanda S; Brewoo JN; Powell TD; Young GR; Das SC; Hatta M; Broman KW; Hungnes O; Dudman SG; Kawaoka Y; Kent SJ; Stinchcomb DT; Osorio JE; Friedrich TC
J Virol; 2014 Nov; 88(22):13418-28. PubMed ID: 25210172
[TBL] [Abstract][Full Text] [Related]
19. Neuraminidase-Inhibiting Antibody Titers Correlate with Protection from Heterologous Influenza Virus Strains of the Same Neuraminidase Subtype.
Walz L; Kays SK; Zimmer G; von Messling V
J Virol; 2018 Sep; 92(17):. PubMed ID: 29925654
[TBL] [Abstract][Full Text] [Related]
20. Cross-Reactive Neuraminidase-Inhibiting Antibodies Elicited by Immunization with Recombinant Neuraminidase Proteins of H5N1 and Pandemic H1N1 Influenza A Viruses.
Liu WC; Lin CY; Tsou YT; Jan JT; Wu SC
J Virol; 2015 Jul; 89(14):7224-34. PubMed ID: 25948745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
